SAB Biotherapeutics, Inc. (SABS)Healthcare | Biotechnology | Miami Beach, United States | NasdaqCM
3.73 USD
-0.09
(-2.356%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.73 |
Hot Take ↕ | July 11, 2026, 6:43 a.m. EDT
The investment case for SAB Biotherapeutics is currently defined by a severe structural deterioration that outweighs any potential catalysts. The company has endured four consecutive years of negative annual returns, culminating in a catastrophic -97.38% cumulative decline over the trailing four-year window. This multi-year trajectory signals that the market has thoroughly repriced the business quality, rendering the current low share price a reflection of deep distress rather than a margin of safety. Fundamentally, the picture is bleak: the company is burning through cash with negative free cash flow, negative operating cash flow, and negative returns on both assets and equity. While recent headlines highlight promising clinical trial results for their Type 1 diabetes treatment, these developments have failed to arrest the bleeding in the stock price or restore investor confidence. The balance sheet, though currently showing low debt relative to equity, is being eroded by persistent operational losses. Furthermore, the options market confirms this pessimism, with traders aggressively buying put protection and avoiding call exposure, suggesting a fear of further downside rather than anticipation of a rally. Without a proven track record of profitability or a clear path to sustainable cash generation, the risk of permanent capital loss remains high. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.058129 |
| AutoTheta | 0.059960 |
| MSTL | 0.061223 |
| AutoETS | 0.064060 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.287 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.716 |
| Market Cap | 285,211,072 |
| Forward P/E | -3.80 |
| Beta | 0.53 |
| Website | https://www.sab.bio |
As of July 11, 2026, 6:43 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (2.1k contracts at the $3 strike) compared to negligible call volume. The implied volatility skew shows traders pricing in significant downside risk, while call activity remains thin and focused on near-term anchors rather than speculative upside plays.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.42007434 |
| Address1 | 777 W 41st St. |
| All Time High | 129.0 |
| All Time Low | 1.0 |
| Ask | 4.83 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,049,500 |
| Average Daily Volume3 Month | 896,155 |
| Average Volume | 896,155 |
| Average Volume10Days | 1,049,500 |
| Beta | 0.53 |
| Bid | 2.73 |
| Bid Size | 2 |
| Book Value | 3.0 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.73 |
| Current Ratio | 11.447 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.84 |
| Day Low | 3.7 |
| Debt To Equity | 2.716 |
| Display Name | SAB Biotherapeutics |
| Earnings Call Timestamp End | 1,778,589,000 |
| Earnings Call Timestamp Start | 1,778,589,000 |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -55,123,040 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.338 |
| Enterprise Value | 183,992,672 |
| Eps Current Year | -1.279 |
| Eps Forward | -0.98075 |
| Eps Trailing Twelve Months | -0.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7128 |
| Fifty Day Average Change | 0.017199993 |
| Fifty Day Average Change Percent | 0.0046326206 |
| Fifty Two Week Change Percent | 42.007435 |
| Fifty Two Week High | 6.6 |
| Fifty Two Week High Change | -2.87 |
| Fifty Two Week High Change Percent | -0.4348485 |
| Fifty Two Week Low | 1.85 |
| Fifty Two Week Low Change | 1.88 |
| Fifty Two Week Low Change Percent | 1.0162162 |
| Fifty Two Week Range | 1.85 - 6.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 41,199,618 |
| Forward Eps | -0.98075 |
| Forward P E | -3.8032117 |
| Free Cashflow | -26,638,508 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 86 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -39,092,988 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00841 |
| Held Percent Institutions | 0.92035 |
| Implied Shares Outstanding | 76,464,094 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,412,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. |
| Long Name | SAB Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 285,211,072 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_268941400 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -9,410,830 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 292,092,839 |
| Number Of Analyst Opinions | 11 |
| Open | 3.79 |
| Operating Cashflow | -51,249,024 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 305 845 2813 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.73 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 3.82 |
| Price Eps Current Year | -2.9163408 |
| Price Hint | 4 |
| Price To Book | 1.2433333 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.058 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0899999 |
| Regular Market Change Percent | -2.35602 |
| Regular Market Day High | 3.84 |
| Regular Market Day Low | 3.7 |
| Regular Market Day Range | 3.7 - 3.84 |
| Regular Market Open | 3.79 |
| Regular Market Previous Close | 3.82 |
| Regular Market Price | 3.73 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 229,924 |
| Return On Assets | -0.25375 |
| Return On Equity | -0.0032 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 76,464,094 |
| Shares Percent Shares Out | 0.0493 |
| Shares Short | 3,773,336 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,644,665 |
| Short Name | SAB Biotherapeutics, Inc. |
| Short Percent Of Float | 0.0512 |
| Short Ratio | 3.34 |
| Source Interval | 15 |
| State | FL |
| Symbol | SABS |
| Target High Price | 16.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 11.18182 |
| Target Median Price | 12.0 |
| Total Cash | 107,391,584 |
| Total Cash Per Share | 1.404 |
| Total Debt | 6,173,123 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.62075 |
| Two Hundred Day Average Change | 0.10925007 |
| Two Hundred Day Average Change Percent | 0.030173326 |
| Type Disp | Equity |
| Volume | 229,924 |
| Website | https://www.sab.bio |
| Zip | 33,140 |